Your Article Summary
See Latest ArticlesPhase Ib study of NGR–hTNF, a selective vascular targeting agent, administered at low doses in combination with doxorubicin to patients with advanced solid tumours
British Journal of Cancer, 07/02/09
Gregorc V et al. - NGR–hTNF plus doxorubicin was administered safely and showed promising activity in patients pre-treated with anthracyclines. The dose level of 0.8 ug m-2 NGR–hTNF plus doxorubicin 75 mg m-2 was selected for phase II development.
Related Articles
iNOS activity is necessary for the cytotoxic and immunogenic effects of doxorubicin in human colon cancer cells
Molecular Cancer, 11/24/09
Relevance Score: 94%
Cisplatin versus cisplatin plus doxorubicin for standard-risk hepatoblastoma
New England Journal of Medicine, 10/22/09
Relevance Score: 92%
Prospective Randomized Study of Doxorubicin-Eluting-Bead Embolization in the Treatment of Hepatocellular Carcinoma: Results of the PRECISION V Study
Cardiovascular and Interventional Radiology, 11/17/09
Relevance Score: 87%
High dose intensity doxorubicin in aggressive non-Hodgkin's lymphoma: a literature-based meta-analysis
Annals of Oncology, 10/29/09
Relevance Score: 87%
Initial cytoreductive treatment with thalidomide plus bolus vincristine/doxorubicin and reduced dexamethasone followed by autologous stem cell transplantation for multiple myeloma
Investigational New Drugs, 10/23/09
Relevance Score: 87%
Today in Pharmacology/Therapy...keeping you current
Receive free subspecialty "5-minute updates" via email
Port central venous catheters–associated bloodstream infection during outpatient-based chemotherapy
Medical Oncology, 12/17/09
A phase Ib/IIa trial to evaluate the CCK2 receptor antagonist Z-360 in combination with gemcitabine in patients with advanced pancreatic cancer
European Journal of Cancer, 12/16/09
A phase II feasibility study of weekly paclitaxel in heavily pretreated advanced gastric cancer patients with poor performance status
Oncology (Karger), 12/16/09